Valuation: Imunon, Inc.

Market Cap 5.11M 4.57M 4.21M 3.81M 7.12M 485M 7.26M 50.17M 20.14M 255M 19.16M 18.76M 804M P/E 2026 *
-0.38x
P/E 2027 * -0.49x
Enterprise Value 5.11M 4.57M 4.21M 3.81M 7.12M 485M 7.26M 50.17M 20.14M 255M 19.16M 18.76M 804M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.18%
Yield 2026 *
-
Yield 2027 * -
1 day+9.24%
1 week-26.32%
Current month-29.46%
1 month-29.46%
3 months-43.12%
6 months-67.84%
Current year-76.12%
1 week 0.81
Extreme 0.8101
1.27
1 month 0.81
Extreme 0.8101
1.38
Current year 0.81
Extreme 0.8101
4.2
1 year 0.81
Extreme 0.8101
4.6
3 years 0.81
Extreme 0.8101
47.61
5 years 0.81
Extreme 0.8101
185.87
10 years 0.81
Extreme 0.8101
2,985.67
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Date Insider Type Main position Quantity % Market Cap. Importance
09/10/26 Free

Chairman

7,800 0.3094%
09/10/26 Free

Chief Executive Officer

2,977 0.1181%
09/10/26 Free

Chief Technology Officer

1,249 0.0495%
Change 5-day change 1-year change 3-year change Capi.($)
+9.24%-26.32%-79.73%-93.02% 5.11M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +1.23%+4.15%+35.10%+176.39% 39.43B
Weighted average by Cap. +0.18%+5.44%+48.50%+186.13%

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.96M -11.92M -10.8M -20.19M -1.37B -20.56M -142M -57.05M -723M -54.29M -53.14M -2.28B -18.55M -16.62M -15.28M -13.85M -25.89M -1.76B -26.37M -182M -73.16M -927M -69.62M -68.14M -2.92B
Net Debt - -
Projected Income Statement - Annual - Imunon, Inc.
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
30/10/26 $0.9100 +9.24% 132,515
29/10/26 $0.8330 +0.35% 211,775
28/10/26 $0.8301 -5.26% 195,020
27/10/26 $0.8762 -28.76% 542,685
26/10/26 $1.230 -0.40% 39,377
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Imunon, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9100USD
Average target price
17.00USD
Spread / Average Target
+1,768.13%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Imunon, Inc.
  1. Stock Market
  2. Stocks
  3. IMNN Stock